Key aspects of the role
You will be:
- chairing all DPFS panel meetings, ensuring decisions on funding proposals are credible and that all members’ views are considered in decision-making
- contributing to the ongoing development of MRC’s translational strategy and ensuring both effective delivery of MRC strategy across the panel remit and that funding decisions reflect strategic priorities
- having oversight of key aspects of post award monitoring
- participating in MRC Strategy Board discussions
The DPFS panel meets three times each year, with two-day meetings taking place in January, May, and September. Typically, around 25 full proposals and 40 to 50 outline proposals are assessed at each meeting. In addition, the DPFS Panel also reviews 20 to 30 applications from the newly established Developmental Pathway Gap Fund.
DPFS projects are milestone-driven with a high level of post-award monitoring. Requests for changes to the timing, scientific plan or budget of project milestones are reviewed by MRC, and where appropriate comment and approval is sought from members of the panel, with input required from the chair in some cases.
The chair will also be involved in strategic decision-making for both DPFS and the wider MRC translational research remit, and will be invited to join MRC’s Strategy Board, which meets four times a year.
It is essential that individuals should be able to commit the necessary time and attention to the role and have the full support of their employer and organisation in doing so.
Conflicts of interest
The high standards of integrity expected by the public and parliament, and for the role, requires the panel chair to avoid situations in which their duties and other interests’ conflict with panel business or where there could be a suspicion of conflict.
Panel chair must not misuse information gained in the course of their work for the MRC for personal gain or for political purpose, nor seek to use the opportunity of public service to promote their private interests, or those of connected organisations, persons, or firms.
Although previous experience with the MRC or another major funder is required, a panel chair cannot be a member of a review panel for a major funder (for example, Wellcome Trust, Cancer Research UK) simultaneously.
Panel chairs will receive an annual stipend plus a per day attendance fee. Travel and subsistence expenses (including family care costs) will be reimbursed.